New personalized vaccine trial aims to boost immune attack on aggressive breast cancer
NCT ID NCT07300475
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing whether a personalized cancer vaccine, made from a patient's own tumor, can safely boost the immune system's ability to fight triple negative breast cancer. About 30 newly diagnosed patients will receive the vaccine along with standard chemotherapy and immunotherapy, with some also getting an additional immune-boosting drug called AB248. The main goals are to check safety, see if the vaccine can be made in time, and measure immune responses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- personalized cancer vaccine (PCV) with or without AB248 (CD8-selective IL-2 mutein fusion protein)
- What this could lead to
- If successful, this could lead to a more effective treatment approach for triple negative breast cancer by training the immune system to fight the cancer more precisely.
- What could go wrong
- This is an early Phase 1 trial with only 30 participants, so it is primarily testing safety and feasibility. The personalized vaccine may not trigger a strong enough immune response, and side effects from the combination therapy are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can a drug duo tame Triple-Negative breast cancer?
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- Could a genetic marker guide future cancer therapies in taiwan?
- New drug targets Hard-to-Treat breast cancer in advanced stage
- New PET tracer could sharpen detection of aggressive breast cancer